Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Finished Goods (2018 - 2025)

Protalix BioTherapeutics has reported Finished Goods over the past 9 years, most recently at $10.4 million for Q4 2025.

  • Quarterly results put Finished Goods at $10.4 million for Q4 2025, up 90.38% from a year ago — trailing twelve months through Dec 2025 was $10.4 million (up 90.38% YoY), and the annual figure for FY2025 was $10.4 million, up 90.38%.
  • Finished Goods for Q4 2025 was $10.4 million at Protalix BioTherapeutics, down from $10.9 million in the prior quarter.
  • Over the last five years, Finished Goods for PLX hit a ceiling of $14.5 million in Q1 2023 and a floor of $706000.0 in Q3 2024.
  • Median Finished Goods over the past 5 years was $8.5 million (2022), compared with a mean of $8.6 million.
  • Biggest five-year swings in Finished Goods: tumbled 91.46% in 2024 and later surged 1446.32% in 2025.
  • Protalix BioTherapeutics' Finished Goods stood at $11.5 million in 2021, then decreased by 7.88% to $10.6 million in 2022, then plummeted by 45.24% to $5.8 million in 2023, then dropped by 6.28% to $5.4 million in 2024, then skyrocketed by 90.38% to $10.4 million in 2025.
  • The last three reported values for Finished Goods were $10.4 million (Q4 2025), $10.9 million (Q3 2025), and $8.6 million (Q2 2025) per Business Quant data.